MedPath

Cycle Pharmaceuticals Ltd.

Cycle Pharmaceuticals Ltd. logo
🇺🇸United States
Ownership
Private
Established
2012-01-01
Employees
51
Market Cap
-
Website
http://www.cyclepharma.com

Clinical Trials

6

Active:0
Completed:6

Trial Phases

1 Phases

Phase 1:6

Drug Approvals

1

FDA:1

Drug Approvals

NITYR

Approval Date
Jan 23, 2024
FDA

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (100.0%)

Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions

First Posted Date
2020-06-02
Last Posted Date
2022-06-08
Lead Sponsor
Cycle Pharmaceuticals Ltd.
Target Recruit Count
32
Registration Number
NCT04411940
Locations
🇿🇦

FARMOVS Clinical Research Organisation, Bloemfontein, Free State, South Africa

Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions

First Posted Date
2020-06-02
Last Posted Date
2022-06-08
Lead Sponsor
Cycle Pharmaceuticals Ltd.
Target Recruit Count
32
Registration Number
NCT04411953
Locations
🇿🇦

FARMOVS Clinical Research Organisation, Bloemfontein, Free State, South Africa

Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride

Phase 1
Completed
Conditions
Anti-Psychotic
Control Manifestations of the Manic Type of Mani-depressive Illness
Control Nausea and Vomiting
Adjunct in the Treatment of Tetanus
Relief of Intractable Hiccups
Management of Manifestations of Psychotic Disorders
Acute Intermittent Porphyria
Treatment of Schizophrenia
Relief of Restlessness and Apprehension Before Surgery
Interventions
First Posted Date
2016-10-24
Last Posted Date
2017-11-14
Lead Sponsor
Cycle Pharmaceuticals Ltd.
Target Recruit Count
20
Registration Number
NCT02943213
Locations
🇿🇦

Farmovs Parexel, Bloemfontein, Kampuslaan Suid, South Africa

Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)

Phase 1
Completed
Conditions
Hereditary Tyrosinemia, Type I
Interventions
First Posted Date
2016-04-25
Last Posted Date
2017-03-15
Lead Sponsor
Cycle Pharmaceuticals Ltd.
Target Recruit Count
20
Registration Number
NCT02750332
Locations
🇿🇦

Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, Free State, South Africa

Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin

Phase 1
Completed
Conditions
Hereditary Tyrosinemia, Type I
Interventions
First Posted Date
2016-04-25
Last Posted Date
2017-03-15
Lead Sponsor
Cycle Pharmaceuticals Ltd.
Target Recruit Count
24
Registration Number
NCT02750709
Locations
🇿🇦

Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein, Free State, South Africa

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.